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Abstract
Neuropathic pain is a common clinical condition. Current treatments are often inadequate, ineffective, or produce
potentially severe adverse effects. Understanding the mechanisms that underlie the development and maintenance
of neuropathic pain will be helpful in identifying new therapeutic targets and developing effective strategies for
the prevention and/or treatment of this disorder. The genesis of neuropathic pain is reliant, at least in part, on
abnormal spontaneous activity within sensory neurons. Therefore, voltage-gated sodium channels, which are
essential for the generation and conduction of action potentials, are potential targets for treating neuropathic pain.
However, preclinical studies have shown unexpected results because most pain-associated voltage-gated channels
in the dorsal root ganglion are down-regulated after peripheral nerve injury. The role of dorsal root ganglion
voltage-gated channels in neuropathic pain is still unclear. In this report, we describe the expression and
distribution of voltage-gated sodium channels in the dorsal root ganglion. We also review evidence regarding
changes in their expression under neuropathic pain conditions and their roles in behavioral responses in a variety
of neuropathic pain models. We finally discuss their potential involvement in neuropathic pain.
Introduction
Neuropathic pain is a chronic condition that affects mil-
lions of people worldwide. It is characterized by pain
hypersensitivity, including spontaneous ongoing or
intermittent burning pain, an exaggerated response to
painful stimuli, and pain in response to normally innoc-
uous stimuli. Because the mechanisms of neuropathic
pain induction and maintenance are far more compli-
cated than previously assumed, current treatments can
be ineffective or produce potentially severe adverse
effects. Understanding molecular mechanisms of this
disorder may allow improvement of its treatment.
It is generally believed that neuropathic pain is caused
by changes in expression and function of receptors,
enzymes, and voltage-dependent ion channels in periph-
eral nerves and dorsal root ganglion (DRG) neurons, as
well as at synapses in the nociceptive pathway in the
central nervous system [1,2]. DRG neurons express
many kinds of ion channels/receptors. These channels
and receptors have at least three functions (Figure 1): 1)
Transduction (e.g., transient receptor potential channels,
sodium channels, acid-sensing ion channels, and ATP-
sensitive receptors that are expressed in the peripheral
terminals of DRG neurons transduce noxious stimuli
into electric impulses), 2) Conduction (e.g., sodium and
potassium channels are involved in the propagation of
action potentials), and 3) Modulation of synaptic trans-
mission (e.g., voltage-gated calcium channels and gluta-
mate receptors that are expressed on presynaptic
terminals of the primary afferents in dorsal horn regu-
late the release of neurotransmitters). After nerve injury,
injured and uninjured DRG neurons become more exci-
table and exhibit ectopic firing [3,4]. It is reasonable to
conclude that this abnormal spontaneous activity might
be related to nerve injury-induced changes in the den-
sity, distribution, and functional activities of voltage-
gated sodium channels in the DRG neurons.
To date, at least nine subtypes of sodium channel have
been cloned and identified on mammalian cells. All
sodium channels consist of a central a-subunit and two
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also referred to as channels) and four b-subunits have
been identified in mammals. The pore-forming a-
subunit determines the primary function of sodium
channels, but the kinetics and voltage-dependence of
channel gating are in part modified by the b-subunits.
The a-subunits form four homologous domains (I-IV),
each of which contains six transmembrane a helices
(S1-S6) and an additional pore loop located between the
S5 and S6 segments. Voltage sensors of sodium channels
are located in the highly conserved S4 transmembrane
segments. Membrane depolarization produces changes
in the transmembrane electric field and causes the S4
segment to spiral outward. This conformational change
opens the pore. Following activation, sodium channels
quickly inactivate to prevent further ion flow through
the pore and to allow repetitive action potential firing of
cells. Most voltage-gated sodium channels can be
blocked by nanomolar concentrations of tetrodotoxin
(TTX) and thereby are termed TTX-sensitive channels.
These TTX-sensitive channels show rapidly activating
and inactivating sodium currents. In contrast, Nav1.5,
Nav1.8, and Nav1.9 are relatively resistant to this toxin
and show sodium currents that are TTX-resistant [5].
Voltage-gated sodium channels can be modulated by
receptors coupled to intracellular signaling molecules
(Figure 2). The modulation can occur through phos-
phorylation of specific residues on the a-subunit after
the activation of cytoplasmic protein kinases. Two pro-
tein kinases, protein kinase A and protein kinase C,
have been shown to target voltage-gated sodium chan-
nels. Both are activated by G-protein-coupled second
messenger systems. The specific amino acid residues
that are phosphorylated by these two kinases are located
primarily on the linker between domains 1 and 2. The
phosphorylation of voltage-gated sodium channels alters
their function [6]. Moreover, the expression of voltage-
gated sodium channels can be up-regulated by neurotro-
phins, including nerve growth factor, brain-derived
neurotrophic factor (BDNF), and glial-derived neuro-
trophic factor (GDNF) (Figure 3) [7-9]. Interestingly,
intrathecal injection of neurotrophin-3 causes significant
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Figure 1 Involvement of dorsal root ganglion (DRG) channels and receptors in the induction and modulation of pain. A variety of DRG
channels and receptors are involved in the transduction of noxious stimuli into electric impulses at the peripheral terminals of DRG neurons
[e.g., transient receptor potential (TRP) channels, voltage-sensitive sodium (Na
+) channels, ATP-sensitive receptors, acid sensing ion channels], in
the conduction of action potentials along the axons [e.g., voltage-sensitive Na
+ channels and potassium (K
+) channels], and in the modulation of
neurotransmitter release at presynaptic terminals of primary afferents in the dorsal horn [e.g., voltage-gated calcium (Ca
2+) channels, GABA
receptors, and glutamate receptors].
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Page 2 of 9decreases in the levels of Nav1.8 and Nav1.9 in L5
DRGs ipsilateral and contralateral to chronic constric-
tion injury (CCI) of sciatic nerve [10]. In addition,
inflammatory cytokines such as tumor necrosis factor a
(TNFa) up-regulate the expression of Nav1.3, Nav1.8,
and Nav1.9 and increase both TTX-sensitive and -resis-
tant currents in the DRG neurons [11,12]. These effects
of neurotrophins and pronociceptive cytokines on
sodium channel expression might be mediated through
regulation of intracellular downstream signaling
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Figure 2 Schematic representation of signaling pathways that modulate Na
+ channels (Nav). The activation of G-protein-coupled
receptors (GPCR) by their ligands activates adenylyl cyclase (AC) and phospholipase C (PLC), which produce cyclic adenosine monophosphate
(cAMP) and diacylglycerol (DAG), respectively. cAMP then activates cAMP-dependent protein kinase (PKA), whereas DAG activates protein kinase
C (PKC). Both PKA and PKC phosphorylate (P) the Na
+ channel to regulate its function.
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Figure 3 Potential mechanisms by which sodium channel (Nav) expression is regulated. Neurotrophins such as nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), and glial-derived neurotrophic factor (GDNF) bind to their respective receptors: tyrosine kinase receptor
(Trk) A, TrkB, and Ret; receptor stimulation then activates the Ras/MEK/MAPK pathway. Activated MAPK promotes expression of sodium channels
at the levels of mRNA and protein through unknown mechanisms (indicated by the red dashed arrows). An inflammatory cytokine, tumor
necrosis factor a (TNFa), also up-regulates expression of sodium channels through activation of the TRAF2/MEK/MAPK pathway. In contrast,
neurotrophin-3 (NT-3) down-regulates the expression of sodium channels through TrkA-mediated inhibition of the Ras/MEK/MAPK pathway
(indicated by the blue dashed arrows). MAPK: mitogen-activated protein kinases; MEK: MAPK kinase; TNFR1: tumor necrosis factor receptor 1;
TRAF2: TNF receptor-associated factor 2.
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mitogen-activated protein kinase (Figure 3) [11,13].
Most sodium channels (except for Nav1.4, which is
predominantly expressed in adult skeletal muscle [14]
and Nav1.5, which is expressed in cardiac tissue) have
been identified in adult DRGs [15]. Their expression
level and the cell types to which they are localized in
the DRG are distinct under normal conditions. Unex-
pectedly, preclinical studies indicate that peripheral
nerve injury down-regulates most pain-associated vol-
tage-gated channels in the injured DRG. Whether and
how voltage-gated channels participate in nerve injury-
evoked ectopic firing in the DRG neurons is still not
unclear. In this review, we describe the expression and
distribution of each sodium channel subtype in the
DRG. We also review evidence regarding changes that
occur in channel expression under neuropathic pain
conditions and their roles in behavioral responses in a
variety of neuropathic pain models. Finally, we discuss
their potential involvement in this disorder.
Nav1.1
Nav1.1 is a TTX-sensitive sodium channel [16,17], but
the current properties of Nav1.1 have not been charac-
terized in DRG neurons. In situ hybridization histo-
chemistry has shown that Nav1.1 mRNA expression in
DRGs is high in large-diameter neurons, moderate in
medium-diameter neurons, and low in small-diameter
neurons [18,19]. Approximately 25-33% of DRG neurons
in naïve rats are positive for Nav1.1 mRNA [20]. Double
immunostaining has shown that most Nav1.1-labeled
cells are positive for NF200 (a marker for myelinated
A-fibers), and that 79.2% of NF200-positive neurons
express Nav1.1 mRNA. Research also has shown that
65.0% of Nav1.1-positive cells co-express neurotrophin-3
receptor tyrosine kinase C (TrkC; a marker for non-
nociceptive mechanosensors) and that 51.6% of TrkC-
labeled DRG cells are positive for Nav1.1 [21]. These
findings indicate that Nav1.1 is expressed predominantly
in the large-diameter A-fiber DRG neurons and that it
might participate mainly in proprioceptive transmission
(Table 1). It should be noted that approximately 11% of
Nav1.1 mRNA-positive DRG neurons are positive for
IB4 (a marker for small non-peptidergic nociceptive
neurons), suggesting that Nav1.1 in these small-diameter
DRG neurons may participate in nociceptive transmis-
sion and modulation [20]. Indeed, mutations in SCN1A
(the gene for Nav1.1) have been associated with inher-
ited epileptic syndromes [22] and familial hemiplegic
migraine in humans [23]. Interestingly, preclinical stu-
dies showed that the level of Nav1.1 mRNA was
decreased in the injured DRG after peripheral spinal
nerve ligation (SNL) or spared nerve injury (SNI)
[24,25]. Thus, whether and how DRG Nav1.1 is involved
in neuropathic pain development is still elusive and
remains to be further studied.
Nav1.2
Nav1.2 is one of the predominant sodium channels in
the central nervous system; it is localized on dendrites,
unmyelinated axons, and premyelinated axons [26]. The
l e v e lo fN a v 1 . 2m R N Ae x p r e s s i o ni nt h ea d u l tD R Gi s
very low [18], although its expression is moderate in
early developmental stages. Peripheral nerve injury and
inflammation do not alter the levels of Nav1.2 mRNA
or protein in the DRG [19,24,25]. The evidence suggests
that DRG Nav1.2 is unlikely to be involved in the devel-
opment of neuropathic pain (Table 1).
Nav1.3
Although Nav1.3 is expressed abundantly in DRG neu-
rons during fetal and neonatal periods, it is normally
undetectable in adult naïve DRG neurons [27]. However,
it can be up-regulated in the injured DRG and ipsilateral
dorsal horn after peripheral nerve injury. Approximately
37.5% of DRG neurons are Nav1.3-positive in the L5
DRG after sciatic nerve lesion and 15.8% after sural
axotomy [28]. In situ hybridization histochemistry
showed that, after L5 SNL, 40.7-47.2% of DRG neurons
were Nav1.3 mRNA-positive cells, most of which were
medium or large in size [20]. A recent study indicated
that L5 ventral root transection produces a TNFa-
dependent increase in Nav1.3 at both the mRNA and
protein levels in the L4 and L5 DRGs [12]. Nav1.3 pro-
tein was also found to accumulate in neuromas of
patients with painful neuropathy [29] and to up-regulate
in second-order dorsal horn neurons after CCI [30].
These findings suggest that an increase in Nav1.3 in
DRG and dorsal horn might be involved in nerve injury-
induced pain hypersensitivities.
Despite the accrued evidence, the role of Nav1.3 in
neuropathic pain behavior is still controversial. Hains
et al. [31] reported that knockdown of DRG Nav1.3 via
intrathecal administration of Nav1.3 antisense oligo-
deoxynucleotides (ASO) attenuated pain hypersensitiv-
ities induced by spinal cord injury and sciatic nerve
CCI. In contrast, Lindia et al. [28] found that intrathecal
administration of Nav1.3 ASO did not attenuate SNI-
induced mechanical or cold allodynia, although it did
significantly block the SNI-induced increase in DRG
Nav1.3. In addition, neuropathic pain development
remained intact in both conventional and conditional
Nav1.3 knockout mice [32]. Furthermore, ectopic dis-
charges from the injured nerves were unaffected in the
absence of Nav1.3 in conventional knockout mice [32].
These results suggest that Nav1.3 is unlikely to be a key
player in the induction of abnormal spontaneous activity
in injured neurons (Table 1).
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Nav1.6 is predominantly located in the Nodes of Ranvier
of both motor and sensory axons in the peripheral and
central nervous systems [33]. In adult DRG, the cellular
distribution pattern of Nav1.6 is similar to that of
Nav1.1. That is, it is highly colocalized with NF200 [20],
indicating that Nav1.6 is an A-fiber-specific channel
(Table 1).
Nerve injury alters expression of DRG Nav1.6. Its
mRNA is down-regulated in the injured L5 DRG follow-
ing SNL and SNI [25]. However, in a rat model of infra-
orbital nerve injury, the level of Nav1.6 protein was
found to be significantly increased proximal to the
lesion site [34], suggesting that it might be transported
quickly to the peripheral terminals under neuropathic
pain conditions. Whether this increase participates in
the generation of abnormal spontaneous activity in the
injured DRG neurons remains to be further studied.
Nav1.7
Nav1.7 is widely expressed in sensory, sympathetic, and
myenteric neurons [18,35,36]. In the DRG, Nav1.7 is
distributed predominantly in small-diameter neurons
[18,19]. Double-labeling studies have shown that most
NF200-negative neurons (>99%) express Nav1.7 mRNA
[20] (Table 1). Nav1.7, as well as Nav1.6, Nav1.8, and
Nav1.9, is present in most intra-epidermal free nerve
endings [37], suggesting that these sodium channels are
poised to participate in amplification of generator poten-
tials, and sets the gain on nociceptors. Nav1.7 displays
slow closed-state inactivation [38]. As a result of this
characteristic, Nav1.7 is unable to respond during high-
frequency stimulation, but it responds to small depolariz-
ing stimuli close to the resting membrane potential [38].
Nav1.7 may be physiologically coupled to Nav1.8 within
DRG neurons. It serves to boost subthreshold stimuli,
resulting in the activation of Nav1.8, which recovers
rapidly from inactivation and produces high-frequency
action potentials [39]. The evidence indicates that Nav1.7
is expressed mainly on C- and Aδ-nociceptive fibers, con-
tributes to amplification of generator potentials, and sets
the gain on nociceptors [40,41]. Indeed, data from animal
studies have indicated that Nav1.7 plays a crucial role in
nociception. Nav1.7 mRNA and protein are up-regulated
Table 1 Summary of sodium channel distribution and potential involvement in pain conditions
Channel Distribution
in normal
DRG
Inflammatory pain Neuropathic pain Effect of manipulation on
behavioral consequences
Human disorders
mRNA Protein mRNA Protein Antisense/
siRNA
Knock out
1.1 High in large
cells, low in
small cells
Unchanged
(carrageenan)
Unchanged
(carrageenan)
Decreased
(SNI, SNL)
N/A N/A N/A Migraine, epilepsy
1.2 Very low in
most
conditions
Unchanged
(carrageenan)
Unchanged
(carrageenan)
Decreased
(SNI, SNL)
N/A N/A N/A Epilepsy
1.3 Extremely low
in adult DRG
Increased
(carrageenan)
Increased
(carrageenan)
Increased
(SNI, SNL)
Increased (SNI,
SNL)
Effective on
SCI and
CCI, but no
effect on
SNI
No effect on
acute,
inflammatory, or
neuropathic pain
Accumulates in
neuromas of human
painful neuropathy
1.6 High in large
cells, low in
small cells
Unchanged
(carrageenan)
Unchanged
(carrageenan)
Decreased
(SNI, SNL)
N/A N/A N/A N/A
1.7 Predominantly
in small cells
Increased
(carrageenan,
CFA)
Increased
(carrageenan,
CFA)
Decreased
(SNI, SNL)
Decreased (SNA,
SNI, and SNL)
Effective on
CFA
Effective on acute
and inflammatory
pain; no effect on
neuropathic pain
Decreased in human
injured DRG;
accumulates in
neuromas; mutations:
PE, PEPD, and CIP
1.8 Exclusively in
small cells
Increased
(carrageenan)
Increased
(carrageenan)
Decreased
(SNI, SNL)
Decreased in L5
DRG (SNL, SNI) but
increased in L4
DRG and sciatic
nerve
Effective on
CFA, SNL,
and CCI
Effective on
inflammatory
pain; no effect on
neuropathic pain
Accumulates in
neuromas of human
painful neuropathy
1.9 Selectively
expressed in
small cells
Increased
(CFA),
unchanged
(carrageenan)
Unchanged
(carrageenan)
Decreased
(SNA, SNI,
and SNL)
Decreased (SNA,
SNI, and SNL)
No effect
on SNL
Effective on
inflammatory
pain; no effect on
neuropathic pain
N/A
Abbreviations: CCI, chronic constrictive injury; CFA, complete Freund’s adjuvant; CIP, channelopathy-associated insensitivity to pain; DRG, dorsal root ganglion; N/
A, not applicable; PE, primary erythermalgia; PEPD, paroxysmal extreme pain disorder; SCI, spinal cord injury; SNA, sciatic nerve axotomy; SNI, spared nerve injury;
SNL, spinal nerve ligation.
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geenan or complete Freund’s adjuvant (CFA) [19,42]. In
addition, knockdown of DRG Nav1.7 significantly pre-
vents the development of hyperalgesia in response to
CFA [43]. Nav1.7 knockout mice also fail to develop
hyperalgesia in several inflammatory pain models (Table
1) [44].
In humans, mutations in the SCN9A gene (which
encodes Nav1.7) are associated with three known pain
disorders: channelopathy-associated insensitivity to pain
(CIP), paroxysmal extreme pain disorder (PEPD), and
primary erythermalgia (PE) [45,46]. Patients with CIP
lose normal response to painful insults such as puncture
wounds, bone fracture, biting, or contact with hot sur-
faces, although other sensory responses are normal [47].
PEPD is characterized by severe burning pain in the rec-
tal, ocular, and submandibular regions, and PE by burn-
ing pain and redness of the extremities [48]. The
evidence indicates that DRG Nav1.7 plays a key role in
acute and inflammatory pain.
In contrast to its role in acute and inflammatory pain,
whether Nav1.7 is involved in nerve injury-induced neu-
ropathic pain is still unclear. Nav1.7 protein and current
are both increased in the DRG in a rat model of painful
diabetic neuropathy [49,50], whereas the amount of
Nav1.7 protein is reduced in the injured DRG after
SNL, SNI, and sciatic nerve axotomy in animals [25,51].
The level of Nav1.7 protein is also decreased in the
injured DRG of humans after peripheral axotomy or
traumatic central axotomy [52], but Nav1.7 protein has
been observed to accumulate in painful neuromas of
amputees with phantom limb pain [29,53]. Interestingly,
a mouse behavioral study showed that conditional
knockout of DRG Nav1.7 did not affect SNL-induced
development of mechanical allodynia [54]. Thus, it
remains questionable whether DRG Nav1.7 has a role in
the development of neuropathic pain.
Nav1.8
Nav1.8 is a sensory neuron-specific voltage-gated
sodium channel that is expressed exclusively in
small-diameter nociceptive DRG neurons [55]. Dou-
ble-labeling studies have shown that 60.0% of
Nav1.8-positive DRG neurons are IB4-positive [20].
Nav1.8 mRNA and protein are increased in DRG
neurons of rodents following injection of carrageenan
into a hind paw [19,56,57]. Knockdown of DRG
Nav1.8 reduces the mechanical allodynia caused by
intraplantar injection of CFA [58]. Furthermore,
Nav1.8 knockout mice display impaired thermal and
mechanical pain hypersensitivity in response to carra-
geenan-induced inflammation [59]. These results
indicate that Nav1.8 in DRG plays a key role in
inflammatory pain (Table 1).
In contrast to inflammatory insult, peripheral nerve
injury down-regulates Nav1.8 mRNA and protein expres-
sion in the small-diameter neurons of the injured DRG
[25,60-62]. This down-regulation might be related to
epigenetic gene silencing. Peripheral nerve injury
up-regulates neuron-restrictive silence factor (NRSF)
expression in the DRG and promotes NRSF binding to
the neuron-restrictive silencer element within the Nav1.8
gene, thereby silencing its expression [63]. Interestingly,
an increase in Nav1.8 protein was observed in the large-
diameter neurons of the uninjured L4 DRG after L5 SNL
[25,64]. After L5 SNL, Nav1.8 immunoreactivity was also
strikingly increased in the uninjured C-fibers of sciatic
nerves [62]. Moreover, intrathecal administration of
Nav1.8 ASO prevented the nerve injury-induced increase
in Nav1.8 in the sciatic nerve [62]. TNFa might partici-
pate in this increase because inhibition of TNFa synth-
esis and knockout of TNFa strongly inhibited nerve
injury-induced up-regulation of DRG Nav1.8 [12]. In
patients with chronic neuropathic pain, Nav1.8 channel
expression was reported to be increased in the nerves
proximal to injury sites [29]. These results suggest that
peripheral nerve injury might trigger TNFa-dependent
translation of Nav1.8 in uninjured DRG neurons and pro-
mote the transportation of Nav1.8 from the uninjured
DRG cell bodies to their axons.
The elevated Nav1.8 in uninjured DRG neurons and
their axons might account, at least in part, for the
abnormal spontaneous activity and behavioral tactile
allodynia observed after nerve injury. Behavioral studies
appear to support this conclusion. Intrathecal adminis-
tration of Nav1.8 ASO attenuated nerve injury-induced
mechanical and thermal hyperalgesia [62], although it
failed to reduce mechanical allodynia in vincristine-
induced neuropathic pain [58]. Small interfering RNAs
that specifically target Nav1.8 were able to reverse
mechanical allodynia in a rat CCI model when adminis-
tered intrathecally [65]. Additionally, a Nav1.8 blocker,
A-803467, dose-dependently attenuated mechanical allo-
dynia in rat neuropathic pain models of SNL and sciatic
nerve injury [66]. Interestingly, neuropathic pain devel-
ops normally in the Nav1.8 knockout mouse [59,67].
Moreover, the use of diphtheria toxin to selectively
delete most nociceptors (> 85%) that predominantly
express Nav1.8 (as well as Nav1.7 and Nav1.9) in mouse
DRG did not affect nerve injury-induced mechanical or
thermal pain hypersensitivities [68]. These conflicting
results indicate that the role of DRG Nav1.8 in neuro-
pathic pain development is still uncertain and needs to
be investigated further.
Nav1.9
Nav1.9 is selectively expressed in small-diameter (<30
μm) DRG neurons. Sixty-two percent of Nav1.9-positive
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highly co-localized with TRPV1, purinergic P2X3 recep-
tor, and B2 bradykinin receptor [69]. Although carragee-
nan injection does not alter the expression of Nav1.9
mRNA or protein in DRG [19], the level of Nav1.9
mRNA in DRG neurons is significantly increased in the
CFA model [70]. Nav1.9 knockout mice exhibit blunted
pain behaviors in response to formalin, carrageenan,
CFA, and prostaglandin E2 [71]. Similar to Nav1.7 and
Nav1.8, DRG Nav1.9 may be required for the develop-
ment of inflammatory pain (Table 1).
In contrast to its involvement in inflammatory pain,
DRG Nav1.9 might not contribute to the development
of neuropathic pain. The levels of Nav1.9 mRNA and
protein, as well as its current density, are reduced in the
DRG after sciatic nerve axotomy [60,72], SNL, and SNI
[25,61]. In addition, intrathecal administration of Nav1.9
ASO has no effect on SNL-induced neuropathic pain
[64]. Intact mechanical and thermal pain hypersensitiv-
ities were observed in Nav1.9 knockout mice after SNI
and partial ligation of the sciatic nerve [69,71]. Current
preclinical evidence does not support a role for DRG
Nav1.9 in the development of neuropathic pain.
Conclusion
Voltage-gated sodium channels conduct sodium ion
influx and control action potential generation. It has
been assumed that DRG voltage-gated sodium channels
participate in induction of neuropathic pain. However,
as summarized in Table 1, most voltage-gated sodium
channels in DRG (with the exception of Nav1.3) are
down-regulated after peripheral nerve injury. This down
regulation is in contrast to the increased expression that
is observed under persistent inflammatory pain condi-
tions. The mechanisms that underlie the expression
changes in neuropathic pain are still unclear. As dis-
cussed above, neurotrophins (e.g., BDNF and GDNF)
and cytokines modulate voltage-gated sodium channel
expression (Figure 3). Up-regulation of the neurotrophic
factors and the release of cytokines cannot explain the
down-regulation of voltage-gated sodium channels in
the DRG under neuropathic pain conditions [73,74].
More importantly, most behavioral findings from animal
models do not support a role for DRG voltage-gated
sodium channels in neuropathic pain (Table 1). Interest-
ingly, the use of sodium channel blockers (such as lido-
caine) in patients can effectively inhibit a variety of
neuropathic pain syndromes [75], although they also
produce significant side effects. Inconsistent results
between clinical and laboratory observations necessitate
careful consideration of the differences between human
and animal models and the methods for pain assess-
ment. Therefore, a possible role for DRG voltage-gated
sodium channel function in neuropathic pain cannot be
excluded and remains to be further investigated.
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